Related Experiment Video
Updated: Jun 6, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Nanaomycin K Inhibited Cell Proliferation and Epithelial-Mesenchymal Transition in Renal Cell Carcinoma
Aya Hiraoka1, Yuto Hirata1, Yuki Kan1
1Department of Public Health, Kobe University Graduate School of Health Sciences.
Abstract:
Nanaomycin K is a natural compound found in the culture broth of "Streptomyces rosa subsp. notoensis" OS-3966. Studies have shown that it inhibits epithelial-mesenchymal transition (EMT), a recognized mechanism of cancer cell migration. Here we investigated the EMT-inhibitory and antitumor effects of nanaomycin K in renal cell carcinoma (RCC). We treated the renal cancer cell line ACHN, Caki-1 and Renca with nanaomycin K and examined its effects on cell proliferation, apoptosis, and expression of EMT and apoptosis markers in vitro and in vivo. Wound healing assays were performed to assess cell migration in vitro, and the mice bearing ACHN tumors were treated intratumorally with nanaomycin K to observe tumor size over time. Nanaomycin K significantly inhibited ACHN, Caki-1 and Renca cell growth and cell migration and significantly induced apoptosis of ACHN in the presence of transforming growth factor (TGF)-β. At the gene level, nanaomycin K increased E-cadherin expression, decreased N-cadherin, Vimentin and Slug expressions, and promoted Caspase-3,8,9 expressions. Intratumor administration of nanaomycin K significantly inhibited tumor growth without apparent adverse events for mice. These results indicate that nanaomycin K inhibit cell growth and EMT in TGF-β-induced advanced RCC, and that nanaomycin K is a potential candidate for the treatment of RCC.
Related Concept Videos
Mitogens and the Cell Cycle
Inhibition of Cdk Activity
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Replicative Cell Senescence
Targeted Cancer Therapies
There are several types of targeted therapies against...

